Article
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery
Registro en:
SENGER, Mario Roberto et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 115, p.1-32, Oct. 2020.
0074-0276
10.1590/0074-02760200254
1678-8060
Autor
Senger, Mario Roberto
Evangelista, Tereza Cristina Santos
Dantas, Rafael Ferreira
Santana, Marcos Vinicius da Silva
Gonçalves, Luiz Carlos Saramago
Souza Neto, Lauro Ribeiro de
Ferreira, Sabrina Baptista
Silva Junior, Floriano Paes
Resumen
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious infection that may break the healthcare system of several countries. Here, we aimed at presenting a critical view of ongoing drug repurposing efforts for COVID-19 as well as discussing opportunities for development of new treatments based on current knowledge of the mechanism of infection and potential targets within. Finally, we also discuss patent protection issues, cost effectiveness and scalability of synthetic routes for some of the most studied repurposing candidates since these are key aspects to meet global demand for COVID-19 treatment.